Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.

Abstract

BACKGROUND:

Inflammatory bowel disease (IBD) is refractory to treatment in one-half of patients.

AIMS:

To evaluate the occurrence of suboptimal therapy among patients with IBD treated with tumor necrosis factor antagonists (anti-TNFs).

METHODS:

A multinational chart review in Europe and Canada was conducted among IBD patients diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) who initiated anti-TNF therapy between 2009 and 2013. The primary endpoint was the cumulative incidence of suboptimal therapy during a two-year follow-up period, defined by the presence of the following indicators: dose escalation, discontinuation, switching, non-biologic therapy escalation, or surgery.

RESULTS:

The study included 1195 anti-TNF initiators (538 UC and 657 CD). The majority of patients (64% of UC and 58% of CD) had at least one indicator of suboptimal therapy. The median time to suboptimal therapy indicator was 12.5 and 17.5 months for UC and CD patients, respectively. Among the 111 UC and 174 CD anti-TNF switchers, 51% and 56% had an indicator of suboptimal therapy, respectively. The median time to suboptimal therapy indicator with the second anti-TNF was 14.3 and 13.0 months for UC and CD patients, respectively.

CONCLUSION:

The majority of IBD patients showed suboptimal therapy with current anti-TNFs.

• Authors: James O Lindsay, Alessandro Armuzzi, Javier P Gisbert, Bernd Bokemeyer, Laurent Peyrin-Biroulet, Geoffrey C Nguyen, Michael Smyth, Haridarshan Patel
• Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (Dig Liver Dis) Vol. 49 Issue 10 Pg. 1086-1091 (Oct 2017) ISSN: 1878-3562 [Electronic] Netherlands
• PMID: 28826571 (Publication Type: Journal Article, Multicenter Study)
• Copyright: Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Chemical References

• Gastrointestinal Agents
• Tumor Necrosis Factor-alpha
• Infliximab
• Adalimumab

Topics

• Adalimumab (administration & dosage, therapeutic use)
• Adult
• Colitis, Ulcerative (drug therapy, surgery)
• Crohn Disease (drug therapy, surgery)
• Disease Progression
• Drug Substitution
• Female
• Follow-Up Studies
• Gastrointestinal Agents (administration & dosage, therapeutic use)
• Humans
• Infliximab (administration & dosage, therapeutic use)
• Male
• Middle Aged
• Quality Indicators, Health Care
• Retrospective Studies
• Time Factors
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)
• Withholding Treatment